Go back

Drug regulator strives to embrace emerging R&D in five-year plan

Medicines agency sets out plan to ensure its work keeps pace with the state-of-the-art

The European Medicines Agency has detailed how it hopes to work more closely with researchers in the coming years, particularly on emerging technologies that hold promise in drug development.

In an update of its five-year strategy, published on 31 March, the agency said it wants to boost its work with researchers who identify disease markers. It wants to encourage them to get these indicators externally validated so they can be used in clinical trials of new drugs.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.